Use of zoledronate for the manufacture of a medicament for the treatment of bone metabolism diseases
CA 2409930 C · Owner: Novartis Ag · Inventors: Galli, Bruno; Schran, Horst; Seaman, John J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2- (imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (soledronic acid) or a pharmaceutically acceptable salt hereof over a period of 15 minutes to a patient in need of said treatment.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 9, 2001 and granted August 28, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 9, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 9, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.